1-anilino-8-naphthalenesulfonate has been researched along with Leukemia, Myelogenous, Chronic, BCR-ABL Positive in 2 studies
1-anilino-8-naphthalenesulfonate: RN given refers to parent cpd
8-anilinonaphthalene-1-sulfonic acid : A naphthalenesulfonic acid that is naphthalene-1-sulfonic acid substituted by a phenylamino group at position 8.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive: Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ponatinib (AP24534) is a potent oral tyrosine kinase inhibitor that blocks native and mutated BCR-ABL, including the gatekeeper mutant T315I, which is uniformly resistant to tyrosine kinase inhibitors." | 2.77 | Ponatinib in refractory Philadelphia chromosome-positive leukemias. ( Bixby, D; Clackson, T; Cortes, JE; Deininger, MW; Druker, BJ; Flinn, I; Haluska, FG; Hu, S; Kantarjian, H; Mauro, MJ; Narasimhan, NI; O'Hare, T; Rivera, VM; Shah, NP; Talpaz, M; Turner, CD, 2012) |
| "We report on 8 chronic myeloid leukemia patients who developed serum lipase/amylase elevation during treatment with nilotinib." | 1.35 | Pancreatic enzyme elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure. ( Amabile, M; Baccarani, M; Castagnetti, F; Gugliotta, G; Luatti, S; Martinelli, G; Palandri, F; Poerio, A; Rosti, G; Soverini, S, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Palandri, F | 1 |
| Castagnetti, F | 1 |
| Soverini, S | 1 |
| Poerio, A | 1 |
| Gugliotta, G | 1 |
| Luatti, S | 1 |
| Amabile, M | 1 |
| Martinelli, G | 1 |
| Rosti, G | 1 |
| Baccarani, M | 1 |
| Cortes, JE | 1 |
| Kantarjian, H | 1 |
| Shah, NP | 1 |
| Bixby, D | 1 |
| Mauro, MJ | 1 |
| Flinn, I | 1 |
| O'Hare, T | 1 |
| Hu, S | 1 |
| Narasimhan, NI | 1 |
| Rivera, VM | 1 |
| Clackson, T | 1 |
| Turner, CD | 1 |
| Haluska, FG | 1 |
| Druker, BJ | 1 |
| Deininger, MW | 1 |
| Talpaz, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 1 Dose Escalation Trial to Determine the Safety, Tolerability and Maximum Tolerated Dose of Oral AP24534 in Patients With Refractory or Advanced Chronic Myelogenous Leukemia and Other Hematologic Malignancies[NCT00660920] | Phase 1 | 81 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| Phase 2 Trial of Ponatinib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST) Following Failure or Intolerance of Prior Therapy With Imatinib[NCT03171389] | Phase 2 | 81 participants (Anticipated) | Interventional | 2017-03-22 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for 1-anilino-8-naphthalenesulfonate and Leukemia, Myelogenous, Chronic, BCR-ABL Positive
| Article | Year |
|---|---|
Ponatinib in refractory Philadelphia chromosome-positive leukemias.
Topics: Adult; Aged; Aged, 80 and over; Amylases; Antineoplastic Agents; Dose-Response Relationship, Drug; D | 2012 |
Ponatinib in refractory Philadelphia chromosome-positive leukemias.
Topics: Adult; Aged; Aged, 80 and over; Amylases; Antineoplastic Agents; Dose-Response Relationship, Drug; D | 2012 |
Ponatinib in refractory Philadelphia chromosome-positive leukemias.
Topics: Adult; Aged; Aged, 80 and over; Amylases; Antineoplastic Agents; Dose-Response Relationship, Drug; D | 2012 |
Ponatinib in refractory Philadelphia chromosome-positive leukemias.
Topics: Adult; Aged; Aged, 80 and over; Amylases; Antineoplastic Agents; Dose-Response Relationship, Drug; D | 2012 |
1 other study available for 1-anilino-8-naphthalenesulfonate and Leukemia, Myelogenous, Chronic, BCR-ABL Positive
| Article | Year |
|---|---|
Pancreatic enzyme elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure.
Topics: Adolescent; Adult; Aged; Amylases; Benzamides; Child; Drug Resistance, Neoplasm; Female; Humans; Ima | 2009 |